Skip to main content
OpenTrials
Completed

NCT Number: NCT01493648

Muscle-Related Side Effects of Statins: Functional Impact, Mechanisms, and Potential Relief With Vitamin D Supplementation

This proposal will explore muscle function (strength and endurance) in men and women suffering from statin-induced muscle symptoms. The mechanisms responsible for these muscle symptoms will be explored. Also, the investigators will assess the potential usefulness of vitamin D supplementation in a randomized control trial.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre hospitalier universitaire de Québec - CHUL

Québec, Quebec, G1V 4G2, Canada

About this study

Statins are a class of drugs that are widely prescribed to lower blood cholesterol levels. Although they have few side effects, many patients report muscle pain, cramps, and weakness when using these drugs. We know very little on the real impact of these muscle symptoms on patient quality of life, especially in relation to muscle strength and endurance.

Patients under statin therapy will stop medication for 2 months. Results from blood sample, muscle function and muscle biopsy (in some participants) will be compared with baseline. Participants will then take vitamin D supplementation or placebo for one month. Thereafter, statin will be reintroduced for two months while continuing vitamin D or placebo supplementation. At the end of that time, measures from blood sample, muscle function and muscle biopsy will be compared with other visits.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • statin therapy
  • healthy and sedentary or moderately physical active

Exclusion criteria

  • Current treatment with other lipid-lowering drugs
  • Natural medicine affecting lipid metabolism
  • CK levels above the normal range
  • Clinical vitamin D deficiency
  • Impaired liver or kidney function
  • Untreated hypo- or hyperthyroidism
  • Treatment with other medications known to increase risk of myopathy
  • Existing infection requiring antibiotic therapy
  • Consumption of greater than 60 ml of grapefruit juice per day
  • Inherited muscle disorders or myopathy
  • Polymyositis or inflammatory myopathy
  • Use of corticosteroids
  • Comorbidities resulting in muscle or bone pain
  • History of elevated CK
  • Unexplained cramps
  • Known sickle cell trait
  • Cancer within the 5 years prior to study entry
  • Diabetes
  • Stroke, coronary artery or peripheral vascular disease
  • Physical disability or previous injury interfering with exercise testing
  • Pregnant or breastfeeding
  • Depression (in last 3 years) or treatment with antidepressants
  • Use of anti-psychotic drugs
  • Alcohol abuse

Treatment and study plan

Vitamin D

Drug

Participants will receive weekly doses of 30,000 IU of vitamin D for 3 months.

Other names: Cholecalciferol, D-tabs

Placebo

Drug

Participants will receive placebo (lactose 100 mg) for 3 months.

Primary outcomes

  1. Change in pain score

    Time frame: Change from baseline at 2 months

  2. Change in muscle function testing

    Time frame: Change from baseline at 2 months

    Strenght and endurance evaluation

Secondary outcomes

  1. Change in muscle histology

    Time frame: Change from baseline at 2 months

    Histological, ultrastructural and metabolic assessment of muscle biopsy.

  2. Change in pain score

    Time frame: Change from baseline at 5 months

  3. Change in muscle function testing

    Time frame: Change from baseline at 5 months

  4. Change in muscle histology

    Time frame: Change from baseline at 5 months

Sponsors and collaborators

Lead sponsor

CHU de Quebec-Universite Laval

Other

Collaborators

  • Canadian Institutes of Health Research (CIHR)
  • Laval University

Registry information

Important dates

Study start
2011
Primary completion
2015
Study completion
2016
First posted
Dec 16, 2011
Registry last updated
Jan 27, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.